Cancer Treatment Results  Survival Rates Cancer Treatments / Therapy Results

Click here to go back to your search results.

Brain Cancer treatment details. Chemotherapy. Radiation. Food and Drug Administration, Rockville, MD, United States

Survival: 12.1 months
Toxicity Grade: 5
Treatments: Chemotherapy
Country: United States
City/State/Province: Rockville, MD
Hospital: Food and Drug Administration
Journal: Link
Date: 10/2005

Patients: This Phase III study involved 573 adults with newly diagnosed glioblastoma multiforme. Most of the patients had undergone surgery, but none had received chemotherapy before the study. The patients were divided into two groups. Group A had 286 patients (109 women, 175 men, 1 did not answer) with a median age of 56 years. Furthermore, at the completion of treatment, 224 patients in both groups were kept on maintenance therapy.

Treatment: In Group A, treatment consisted of radiotherapy. Maintenance therapy consisted of the chemotherapeutic agent temozolomide.

Toxicity: Thirty-two patients died during or within 30 days after the end of treatment. In Group A, 74 patients (26%) reported having grade 3-4 toxicities, including fatigue, headaches, convulsions, confusion, dyspnea, blurred vision, and weakness.

During the maintenance phase, 82 patients (37%) reported having grade 3-4 toxicities, including fatigue, headache, thrombocytopenia, convulsions, vomiting, and weakness.

Results: For Group A (radiotherapy alone), the median overall survival was 368 days (12.1 months). For Group B (radiotherapy and temozolomide), the median overall survival was 444 days (14.6 months). By approving temozolomide, the authors concluded, "newly diagnosed glioblastoma multiforme patients receiving concomitant temozolomide + radiotherapy followed by maintenance temozolomide had significantly improved overall survival compared with patients receiving radiation therapy alone. Therapy was generally well tolerated. This trial represents an important stepping stone along the path of improved glioblastoma therapy."

Correspondence: Martin H. Cohen

E-mail to a Friend Email Physician More Information